ENTROPY NEURODYNAMICS LIMITED — Director's Dealing 2020

Nov 9, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:	Exopharm Limited
ABN:	78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Jason M Watson
Date of last notice	16 September 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	Watson Practice Company Pty Ltd <WatsonPractice A/C> (Director and Controller)
Date of change	9 November 2020
No. of securities held prior to change	290,000 Fully Paid Ordinary Shares
Class	Unlisted Performance Rights
Number acquired	90,000
Number disposed	Nil
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	Unlisted Performance Rights issued for nilconsiderationpursuanttotheCompany’sPerformance Rights Plan as set out in the Noticeof EGM released to the ASX on 24 September2020 and approved by shareholders on 29October 2020.

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change 290,000 Fully Paid Ordinary Shares 90,000 Unlisted Performance Rights Nature of change Issue of Unlisted Performance Rights pursuant to Example: on-market trade, off-market trade, exercise of options, issue the Company’s Performance Rights Plan as of securities under dividend reinvestment plan, participation in buyback approved by Shareholders on 29 October 2020

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the N/A trade to proceed during this period? If prior written clearance was provided, on what date was N/A this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011